IMV Inc. (NASDAQ:IMV) (TSE:IMV) CEO Frederic Ors tells Proactive the Canadian biotechnology company is at the validation stage of advancing its vaccine candidate to help prevent the coronavirus.
Ors explains how the biotech, which has experience carrying out clinical trials in oncology, is developing a vaccine that is unique to its peers’.
